



ASX/MEDIA RELEASE

22 November 2017

Brand Specific, National Reimbursement Granted in Spain for metastatic colorectal cancer (mCRC)

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) is pleased to announce that the Spanish Ministry of Health, Social Services and Equality has included Selective Internal Radiation Therapy (SIRT) with SIR-Spheres® Y-90 resin microspheres in the Basic Portfolio of Services which allows reimbursement by hospitals and regions.

In making this decision, the Ministry's Evaluation Agency commented that SIR-Spheres resin microspheres have shown therapeutic effectiveness and safety in patients with hepatic metastases from colorectal cancer, refractory or intolerant to other treatments.

Mr Andrew McLean, Chief Executive Officer of Sirtex Medical Limited said "We are delighted to receive this product specific reimbursement in Spain, with similar pricing structures to other more established European markets. This is the second Western European market after France earlier this year to grant national reimbursement specifically for Sirtex's SIR-Spheres Y-90 resin microspheres only."

Mr McLean continued "Although SIR-Spheres microspheres are available across a small number of treatment centres in Spain, to date funding for the product has been sporadic and determined at the hospital level, or for self-pay patients only. With this new national reimbursement in place, we expect an acceleration in dose sales growth in this market, commencing around the first quarter of CY18. Accordingly, we will immediately execute on our plans to expand the number of treatment centres certified to use our product, coupled with increased sales and marketing activity to drive new referrals for treatment under this reimbursement to eligible mCRC patients."

The estimated annual incidence of colorectal cancer in Spain was approximately 32,000 cases in 2012; it is also the country's second most common cause of cancer mortality, accounting for approximately 15,000 deaths each year¹.

The Spanish National Healthcare System (Instituto Nacional de la Salud) provides universal healthcare coverage to all Spanish nationals, with close to 100% population coverage.

- ENDS -

About Colorectal Cancer

Colorectal cancer (CRC or bowel cancer) occurs when cancerous cells develop in the patient's colon or rectum. CRC is the third most common form of cancer worldwide, making up about 10% of all cancers. In 2012, an estimated 1.4 million new cases were diagnosed globally and 694,000 cancer deaths were attributed to CRC.²

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 80,000 doses supplied and administered over 1,090 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:

<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**

Visit us on LinkedIn: **Sirtex Medical Limited**

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

¹ Ferlay J *et al.* GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on 17/11/2016.

² World Cancer Report, 2014; Geneva, WHO: 2014; 1.1.